The global market for long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing is experiencing robust growth, propelled by technological advancements in sequencing and an increasing focus on genomics research. A recent report added to ResearchAndMarkets.com’s offerings projects the market to expand from $1.34 billion in 2025 to $1.59 billion in 2026, reflecting a compound annual growth rate (CAGR) of 18.6%1. This growth is largely driven by heightened investments in genomics, a surge in transcriptome research, and the widespread adoption of sequencing platforms such as those from Pacific Biosciences and Oxford Nanopore.
Looking ahead, the market is anticipated to reach $3.18 billion by 2030, with a sustained CAGR of 18.9%. Several factors contribute to this growth trajectory, including the rising demand for precision medicine, the integration of artificial intelligence in bioinformatics tools, and the increasing application of sequencing in rare disease research and clinical transcriptomics. Additionally, the development of cost-efficient long-read sequencing workflows is a significant factor in this market expansion2.
Key trends influencing the market include the growing adoption of single-cell full-length cDNA sequencing and the heightened demand for high-fidelity long-read platforms. Moreover, there is an expanded application of sequencing for detecting alternative splicing. Research organizations are placing greater emphasis on transcript isoform characterization and advanced library preparation kits, creating opportunities for technology developers, clinical laboratories, biotechnology firms, and pharmaceutical companies.
The emphasis on precision medicine is a major catalyst for market growth. As the need for effective treatments for complex and therapy-resistant diseases increases, there is a corresponding demand for detailed molecular information to guide therapeutic decisions. Long-read full-length cDNA sequencing provides critical insights into transcript isoforms and actionable biomarkers, aiding researchers and clinicians in selecting targeted therapies.
Regulatory trends reflect this momentum in personalized treatment development. According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 16 new personalized therapies for rare diseases in 2023, a significant increase from six approvals in 2022. This underscores the growing importance of genomics and transcriptomics in drug development, biomarker discovery, and clinical research3.
Technology providers are responding to these demands by developing high-fidelity single-molecule sequencing platforms and optimized workflows designed to improve transcript accuracy and identify complex RNA isoforms. For example, in December 2023, Pacific Biosciences of California introduced Kinnex RNA kits to advance long-read RNA research. These kits combine high-fidelity sequencing technology with optimized library preparation workflows, generating accurate transcriptome data. They offer ultra-long reads that span entire transcripts, high consensus accuracy, and compatibility with complex RNA samples, supporting the identification of alternative splicing events, fusion transcripts, and previously undiscovered isoforms4.
Strategic partnerships are also enhancing long-read single-cell transcriptomics capabilities. In February 2026, ArgenTag partnered with Pacific Biosciences to merge highly accurate long-read sequencing platforms with single-cell analysis methods. This collaboration aims to enable deeper cellular transcriptome profiling and improve the discovery and characterization of complex biological mechanisms. Such partnerships highlight the market’s increasing focus on integrated sequencing and analysis solutions.
Regionally, North America was the largest market for long-read full-length cDNA sequencing in 2025, supported by established genomics infrastructure, significant research investment, and strong adoption of advanced sequencing platforms. However, the Asia-Pacific region is expected to be the fastest-growing market during the forecast period, driven by the increasing adoption of advanced sequencing technologies and growing research activities. The market spans multiple regions, including Asia-Pacific, Southeast Asia, Western Europe, and others, covering countries such as the United States, China, Japan, and Germany.
The market is segmented by technology, product type, sample type, application, and end-users. Technologies include Pacific Biosciences Single-Molecule Real-Time (PacBio SMRT) and Oxford Nanopore, among others. Product types range from sequencing platforms and reagents to data analysis software. Applications span transcriptome analysis, gene expression studies, and alternative splicing detection, with end-users including academic institutes, pharmaceutical companies, and clinical laboratories.
Footnotes:
- The market is projected to grow from $1.34 billion in 2025 to $1.59 billion in 2026. Source.
- The market is expected to reach $3.18 billion by 2030, with a CAGR of 18.9%. Source.
- The FDA approved 16 new personalized therapies for rare diseases in 2023. Source.
- Pacific Biosciences launched Kinnex RNA kits in December 2023. Source.
Featured Image: Megapixl @ Adiruch